Actively Recruiting

All Genders
ID06366048

A Model Based on Resected Normal Liver Parenchymal Volume (RNLV) to Predict the Risk of Post-Hepatectomy Liver Failure (PHLF)

Led by National Natural Science Foundation of China · Updated on 2026-04-14

1600

Participants Needed

3

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the relationship between the volume of normal liver tissue removed during surgery, called resected normal liver parenchymal volume (RNLV), and the risk of liver failure after liver surgery (post-hepatetotomy liver failure, or PHLF). This observational study focuses on patients diagnosed with hepatocellular carcinoma (HCC) or intracholangiocarcinoma (ICC) who have undergone liver resection. The goal is to build and assess a personalized predictive model using RNLV to better estimate the risk of PHLF before surgery. The study collects data retrospectively from over a thousand patients treated at the investigator’s center. Patients are grouped based on whether they developed liver failure after surgery, defined by two sets of criteria known as the 50-50 criteria and ISGLS criteria. The research evaluates how well the RNLV-based model predicts PHLF and compares its usefulness to other methods, especially for patients with large or multiple liver tumors. Participants' medical records and surgical details are reviewed to calculate RNLV and assess liver failure outcomes within 30 days after surgery. The main outcome is the predicted probability of PHLF using the newly developed model. This approach aims to improve preoperative risk assessment to support safer liver surgeries. The study is sponsored by the National Natural Science Foundation of China and runs through the end of 2026.

CONDITIONS

Brief Title

A Study on Relationship Between Resected Normal Liver Parenchymal Volume(RNLV)and Post-Hepatectomy Liver Failure (PHLF)

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Underwent selective hepatectomy surgery
  • Histologically confirmed diagnosis of hepatocellular carcinoma (HCC) or intracholangiocarcinoma (ICC)
  • Complete and accessible medical data available
Not Eligible

You will not qualify if you...

  • History of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)
  • History of portal vein embolism (PVE)
  • History of tumor rupture
  • Emergency surgery
  • Pathological diagnosis other than HCC or ICC
  • Concomitant resection of gastrointestinal organs, spleenectomy, or other organs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Up to 30 days post-surgery

Participants undergo selective hepatectomy surgery and immediate post-operative care following their procedure.

Multiple visits during hospitalization and follow-up within 30 days after surgery

Post-operative Follow-up

Duration - Up to 30 days post-surgery

Participants are monitored post-surgery to evaluate liver function and assess risk of post-hepatectomy liver failure (PHLF) based on resected normal liver parenchymal volume (RNLV).

Visits as part of standard clinical follow-up within 30 days after surgery

Trial Site Locations

Total: 3 locations

1

Mengchao Hepatobiliary Hospital of Fujian Medical University

Fujian, Shanghai Municipality, China

Actively Recruiting

2

The Third Affiliated Hospital of Naval Medical University

Shanhai, Shanghai Municipality, China, 201800

Actively Recruiting

3

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Mengchao Hepatobiliary Hospital of Fujian Medical University

Shenzhencun, Shanghai Municipality, China

Actively Recruiting

Loading map...

Research Team

Y

Yuan-yuan Wang

G

Gang Huang

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Assessment of the Pharmacokinetic Profile of Tacrolimus Medi...

Liver Failure

Actively Recruiting

2 locations

Clinical Retrospective Study Analysis of Postoperative Compl...

Liver Failure

Actively Recruiting

1 location

A Phase 1/2, Open-Label, Single-Arm Study to Evaluate the Sa...

Liver Diseases

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.

George N Ioannou, Pamela Green, Kathleen F Kerr...

https://pubmed.ncbi.nlm.nih.gov/31145929

Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis.

Qing-Song Xie, Zi-Xiang Chen, Yi-Jun Zhao...

https://pubmed.ncbi.nlm.nih.gov/32988708